| __timestamp | Iovance Biotherapeutics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 14400000 |
| Thursday, January 1, 2015 | 999000 | 33800000 |
| Friday, January 1, 2016 | 978000 | 35900000 |
| Sunday, January 1, 2017 | 952000 | 1254000 |
| Monday, January 1, 2018 | 956000 | 4889000 |
| Tuesday, January 1, 2019 | 8122999 | 7400000 |
| Wednesday, January 1, 2020 | 8712000 | 10100000 |
| Friday, January 1, 2021 | 13980000 | 14300000 |
| Saturday, January 1, 2022 | 21135000 | 23200000 |
| Sunday, January 1, 2023 | 10755000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing insights
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc. have shown intriguing trends in their cost of revenue over the past decade. From 2014 to 2023, Neurocrine's cost of revenue surged by approximately 175%, peaking in 2023. This reflects their aggressive expansion and investment in innovative therapies. Meanwhile, Iovance's costs have fluctuated, with a notable spike in 2022, marking a 120% increase from 2014. This variability underscores the challenges and opportunities in the biotech sector, where strategic investments can lead to significant breakthroughs. As these companies navigate the complexities of drug development, their financial strategies offer valuable insights into the industry's future. Stay tuned as we delve deeper into the financial narratives shaping the biotech world.
Cost Insights: Breaking Down Johnson & Johnson and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Trends: Pfizer Inc. vs Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Iovance Biotherapeutics, Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Amneal Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.
MorphoSys AG vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc.